Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,001 INR | +0.39% | +6.27% | +31.58% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 32.77 and 27.56 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.58% | 2.35B | C+ | ||
+26.47% | 664B | C+ | ||
+26.74% | 567B | B | ||
-6.33% | 354B | C+ | ||
+19.35% | 330B | B- | ||
+4.23% | 286B | C+ | ||
+13.43% | 234B | B+ | ||
+4.71% | 199B | B- | ||
-9.53% | 196B | A+ | ||
-4.04% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- APLLTD Stock
- Ratings Alembic Pharmaceuticals Limited